DAVID MEYER: Open Payments
NPI 1811957459 · PADUCAH, KY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$921 in 42 payments from 12 companies in 2025. Trend: 2023 $1,538 · 2024 $2,000 · 2025 $921
Food & beverage: $921
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 9 | $208 |
| Teva Pharmaceuticals USA, Inc. | 8 | $170 |
| Axsome Therapeutics, Inc. | 5 | $103 |
| Otsuka America Pharmaceutical, Inc. | 4 | $82 |
| Vanda Pharmaceuticals Inc. | 3 | $77 |
| ABBVIE INC. | 3 | $75 |
| Neurocrine BioSciences, Inc. | 3 | $74 |
| Tris Pharma Inc | 3 | $57 |
| Alkermes, Inc. | 1 | $25 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
Products named: CAPLYTA, AUSTEDO XR, Auvelity, VRAYLAR, INGREZZA, Dyanavel XR, FANAPT, REXULTI.
Industry payments across KY — which companies pay providers there.
